Advertisement

Blastic Plasmacytoid Dendritic Cell Neoplasm

  • Daniel KerrIIEmail author
  • Ling Zhang
  • Lubomir Sokol
Leukemia (PH Wiernik, Section Editor)
  • 64 Downloads
Part of the following topical collections:
  1. Topical Collection on Leukemia

Opinion statement

While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes. For this reason, the standard approach for eligible patients has been high-dose induction chemotherapy preferably with acute lymphoblastic leukemia (ALL)-based regimens followed by consolidation with allogeneic hematopoietic stem cell transplantation (alloHSCT). Unfortunately, many patients with this disease are elderly and/or frail and cannot tolerate this therapy, and the low-dose regimens being used in this population are generally not as effective. However, this paradigm may be changing with the advent of newer targeted therapies, particularly the exploitation of CD123. SL-401 has shown very promising results with manageable toxicities and durable responses and appears to be a viable option for elderly or frail patients who are not eligible for transplant. The other CD123-directed therapies, especially chimeric antigen receptor-therapy (CAR-T), may also give promising results in trials that are currently underway. CAR-T has shown promise in a number of other hematologic malignancies, and toxicities have become more manageable as its use is becoming more widespread. While SL-401 has shown potential to provide durable responses even without transplant, we do not yet know whether it will be effective as a means to avoid transplant in patients who are otherwise eligible. All transplant-eligible patients should undergo alloHSCT consolidation given the current available data indicating this is the optimal approach to achieve a long-term remission. Once the CD123-directed therapies are established as standard regimens, future studies may be designed to investigate whether these therapies can be utilized without the use of transplant. Furthermore, combination therapy using anti-CD123 agents with high-dose induction chemotherapy or other low-dose regimens for elderly/frail patients should be investigated. Given the promising results in early clinical trials, it appears CD123 is the most viable target for BPDCN, and future studies should continue to exploit its expression on BPDCN cells.

Keywords

BPDCN Leukemia CD123 Bone marrow transplant SL-401 Venetoclax 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.  https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMedGoogle Scholar
  2. 2.
    Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58–69.PubMedGoogle Scholar
  3. 3.
    Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279–89.  https://doi.org/10.1177/107327481402100404.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang S, Wang X, Liu M, Bai O. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. Ann Hematol. 2018;97(4):563–72.  https://doi.org/10.1007/s00277-018-3259-z.CrossRefPubMedGoogle Scholar
  5. 5.
    Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38(5):673–80.  https://doi.org/10.1097/PAS.0000000000000156.CrossRefPubMedGoogle Scholar
  6. 6.
    Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–46.  https://doi.org/10.3324/haematol.2012.072645.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Swerdlow S, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Vardiman, JW. WHO Classification of tumours of haematopoietic and lymphoid tissues, Fourth Edition 2008. 439Google Scholar
  8. 8.
    Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16–23.  https://doi.org/10.1182/asheducation-2016.1.16.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–81.  https://doi.org/10.18632/oncotarget.7101.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kerr D 2nd, Sokol L. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. Expert Opin Investig Drugs. 2018;27(9):733–9.  https://doi.org/10.1080/13543784.2018.1512970.CrossRefPubMedGoogle Scholar
  11. 11.
    Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556–63.CrossRefGoogle Scholar
  12. 12.
    Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–46.  https://doi.org/10.1038/sj.bmt.1704215.CrossRefPubMedGoogle Scholar
  13. 13.
    Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91(3):283–6.  https://doi.org/10.1002/ajh.24258.CrossRefPubMedGoogle Scholar
  14. 14.
    Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010;34(4):438–46.  https://doi.org/10.1016/j.leukres.2009.09.006.CrossRefPubMedGoogle Scholar
  15. 15.
    Hyakuna N, Toguchi S, Higa T, Okudaira T, Taira N, Masuda M, et al. Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2004;42(7):631–4.  https://doi.org/10.1002/pbc.20034.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim HS, Kim HJ, Kim SH, Choi JY, Ko YH, Kim WS, et al. Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. Korean J Intern Med. 2017;32(5):890–9.  https://doi.org/10.3904/kjim.2015.406.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gilis L, Lebras L, Bouafia-Sauvy F, Espinouse D, Felman P, Berger F, et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma. 2012;53(8):1633–7.  https://doi.org/10.3109/10428194.2012.656627.CrossRefPubMedGoogle Scholar
  18. 18.
    Gruson B, Vaida I, Merlusca L, Charbonnier A, Parcelier A, Damaj G, et al. L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2013;163(4):543–5.  https://doi.org/10.1111/bjh.12523.CrossRefPubMedGoogle Scholar
  19. 19.
    Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a north American multicentre collaborative study. Br J Haematol. 2017;179(5):781–9.  https://doi.org/10.1111/bjh.14954.CrossRefPubMedGoogle Scholar
  20. 20.
    Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440–6.  https://doi.org/10.1182/blood-2012-08-448613.CrossRefPubMedGoogle Scholar
  21. 21.
    Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559–62.  https://doi.org/10.1182/blood-2015-01-621268.CrossRefPubMedGoogle Scholar
  22. 22.
    Steinberg A, Kansal R, Wong M, Lopez A, Lim S, Lopategui J, et al. Good clinical response in a rare aggressive hematopoietic neoplasm: plasmacytoid dendritic cell leukemia with no cutaneous lesions responding to 4 donor lymphocyte infusions following transplant. Case Rep Transplant. 2011;2011:651906.  https://doi.org/10.1155/2011/651906.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Unteregger M, Valentin A, Zinke-Cerwenka W, Troppan K, Deutsch A, Cerroni L, et al. Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplant. 2013;48(6):799–802.  https://doi.org/10.1038/bmt.2012.242.CrossRefPubMedGoogle Scholar
  24. 24.
    Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. Haematologica. 2010;95(2):303–10.  https://doi.org/10.3324/haematol.2009.010611.CrossRefPubMedGoogle Scholar
  25. 25.
    Khwaja R, Daly A, Wong M, Mahé E, Cerquozzi S, Owen C. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma. 2016;57(11):2720–2.  https://doi.org/10.3109/10428194.2016.1160084.CrossRefPubMedGoogle Scholar
  26. 26.
    Laribi K, Denizon N, Ghnaya H, Atlassi M, Besançon A, Pineau-Vincent F, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol. 2014;93(1):81–5.  https://doi.org/10.1111/ejh.12294.CrossRefPubMedGoogle Scholar
  27. 27.
    Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6(9):3493–8.PubMedGoogle Scholar
  28. 28.
    Arranto C, Tzankov A, Halter J. Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate. Ann Hematol. 2017;96(4):681–2.  https://doi.org/10.1007/s00277-016-2907-4.CrossRefPubMedGoogle Scholar
  29. 29.
    Leitenberger JJ, Berthelot CN, Polder KD, Pro B, McLaughlin P, Jones D, et al. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008;58(3):480–4.  https://doi.org/10.1016/j.jaad.2007.12.012.CrossRefPubMedGoogle Scholar
  30. 30.
    Betrian S, Guenounou S, Luquet I, et al. Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia. Hematol Oncol. 2017;35(2):252–5.  https://doi.org/10.1002/hon.2252.CrossRefPubMedGoogle Scholar
  31. 31.
    Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, de Padova N, Becker PS. Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2017;92(5):E75–E7.  https://doi.org/10.1002/ajh.24696.28224664.
  32. 32.
    Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575–81.CrossRefGoogle Scholar
  33. 33.
    Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998;9(4):490–6.  https://doi.org/10.1021/bc980015a.CrossRefPubMedGoogle Scholar
  34. 34.
    Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2(1):19–36.CrossRefGoogle Scholar
  35. 35.
    Jedema I, Barge RM, Frankel AE, Willemze R, Falkenburg JH. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Exp Hematol. 2004;32(2):188–94.  https://doi.org/10.1016/j.exphem.2003.11.005.CrossRefPubMedGoogle Scholar
  36. 36.
    Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100(2):223–30.  https://doi.org/10.3324/haematol.2014.111740.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    • Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.  https://doi.org/10.1182/blood-2014-04-566737This was the first trial reporting activity for SL-401. All of these patients had relapsed/refractory disease and most received only 1 cycle of therapy. Despite the minimal therapy, there was still a 55% CR rate with some very durable responses (ie., 20+ months).CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    • Pemmaraju N, Kendra S, Lane A, Stein A, Vasu S, Blum W, et al. Results of pivotal phase 2 trial of SL-401 in patients with blastic plasmacytoid dendritic cll neoplasm (BPDCN). Blood. 2017;130:1298 These are early results from a phase 2 study using SL-401 as continuous therapy in BPDCN. This abstract reports high ORR for both first-line and refractory patients. Median OS was not reached in first-line therapy. They also reported 31% CR in the refractory patients.Google Scholar
  39. 39.
    Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848–58.  https://doi.org/10.1182/bloodadvances.2018017517.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25(8):1933–45.  https://doi.org/10.1016/j.ymthe.2017.04.017.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343–54.  https://doi.org/10.1182/blood-2013-09-529537.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596–605.  https://doi.org/10.1038/leu.2014.62.CrossRefPubMedGoogle Scholar
  43. 43.
    DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2018. doi:  https://doi.org/10.1182/blood-2018-08-868752. blood-2018-08-868752.
  44. 44.
    • Di Nardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–7.  https://doi.org/10.1002/ajh.25000This study used venetoclax in combination with other low-intensity therapies, including HMAs, in patients with relapsed/refractory myeloid malignancies as well as 2 BPDCN patients. The BPDCN patients both exhibited response to treatment. Overall, the combination regimens were well tolerated.CrossRefGoogle Scholar
  45. 45.
    • Montero J, Stephansky J, Cai T, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017;7(2):156–64.  https://doi.org/10.1158/2159-8290.CD-16-0999In this study, the authors report in vivo activity of venetoclax that was dependent on BCL2 activity. They also report use of venetoclax as single-agent therapy in 2 patients with relapsed BPDCN.CrossRefPubMedGoogle Scholar
  46. 46.
    Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, et al. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report. Medicine (Baltimore). 2017;96(51):e9452.  https://doi.org/10.1097/MD.0000000000009452.CrossRefGoogle Scholar
  47. 47.
    Agliano A, Martin-Padura I, Marighetti P, Gregato G, Calleri A, Prior C, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163–73.  https://doi.org/10.1158/1078-0432.CCR-11-0212.CrossRefPubMedGoogle Scholar
  48. 48.
    Philippe L, Ceroi A, Bole-Richard E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102(11):1861–8.  https://doi.org/10.3324/haematol.2017.169326.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology and Medical OncologyMoffitt Cancer Center/University of South FloridaTampaUSA
  2. 2.Moffitt Cancer CenterDepartment of PathologyTampaUSA

Personalised recommendations